Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Relmada Therapeutics, Inc. - Common Stock (NQ:RLMD)

0.5941 +0.0310 (+5.51%)
Streaming Delayed Price Updated: 9:40 AM EDT, Aug 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Relmada Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Earnings Scheduled For August 7, 2025
 
Via Benzinga
Why Medpace Shares Are Trading Higher By 45%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Earnings Scheduled For May 12, 2025
 
Via Benzinga
Tuesday's session: top gainers and losers
Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
In today's session, these stocks are experiencing unusual volume.
Let's have a look at the stocks with an unusual volume in today's session. 
Via Chartmill
Insights Ahead: Relmada Therapeutics's Quarterly Earnings
 
Via Benzinga
A Look Ahead: Relmada Therapeutics's Earnings Forecast
 
Via Benzinga
Keep an eye on the top gainers and losers in Tuesday's session.
Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
These stocks are gapping in today's session
Let's delve into the US markets on Tuesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
Via Chartmill
Top movers in Tuesday's pre-market session
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Curious about the stocks that are showing activity after the closing bell on Monday?
The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today. 
Via Chartmill
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Top movers analysis one hour before the close of the markets on 2025-04-28: top gainers and losers in today's session.
Wondering how the US markets performed one hour before the close of the markets on Monday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
These stocks have an unusual volume in today's session
Let's have a look at the stocks with an unusual volume in today's session. 
Via Chartmill
Stay updated with the stocks that are on the move in today's pre-market session.
Discover the top movers in Thursday's pre-market session and stay informed about market dynamics. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Why ServiceNow Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Top movers in Wednesday's after hours session
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Top movers in Wednesday's session
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
On Wednesday, there are stocks with unusual volume. Let's take a look.
These stocks have an unusual volume in today's session 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Earnings Scheduled For March 27, 2025
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Relmada Therapeutics Stock Plummets Losing 80% Value - Here's Why
Relmada Therapeutics reports interim analysis of the Phase 3 Reliance II study for REL-1017 in major depressive disorder, indicating futility in meeting efficacy goals. 
Via Benzinga
Nasdaq Surges 150 Points; ISM Services PMI Falls In November
 
Via Benzinga
Dow Gains 250 Points; Salesforce Shares Jump After Q3 Results
 
Via Benzinga
Topics Stocks
RLMD Stock Earnings: Relmada Therapeutics Beats EPS for Q2 2024
RLMD stock results show that Relmada Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.